Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia - Concepedia

Concepedia

Publication | Open Access

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

DOI Full Paper Access

101

Citations

41

References

2020

Year

Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Lynne V. Abruzzo, Barbara L. Andersen, Farrukh T. Awan, Seema A. Bhat, Allison Dean, Margaret S. Lucas, Christin Banks,

Journal of Clinical Oncology

Abstract

The combination regimen of obinutuzumab, ibrutinib, and venetoclax offers time-limited treatment that results in deep remissions and is now being studied in phase III cooperative group trials.

References

	Year	Citations

Page 1